CorpDigest
Johnson & Johnson
Leadership History
4 leaders · Full leadership timeline
Last reviewed: 2026-06-03 · By Swet Parvadiya
J&J is one of only two U.S. Corporations holding an AAA credit rating from all three major rating agencies simultaneously. The second is Microsoft. That financial standing — rarer than most people realize — gave J&J the acquisition capability to spend $29.7 billion on Abiomed and Shockwave Medical within a 30-month window, funding both with debt at rates most companies cannot access. The AAA rating is a competitive weapon in healthcare M&A. The 2023 Kenvue spinoff ended 137 years of consumer health. Tylenol, Band-Aid, Neutrogena, Listerine — the brands that built J&J's public recognition — left the corporate structure in an IPO that valued the consumer unit at roughly $40 billion. What remained was a focused pharmaceutical and medical device company generating $88.821 billion in FY2024 net sales across its pharmaceutical and MedTech segments. The spinoff was not a divestiture of weakness. It was a concentration of strategic resources toward higher-margin, harder-to-imitate business lines. Darzalex, the multiple myeloma treatment developed with Genmab, is approaching $15 billion in annual peak sales potential. The drug demonstrates how J&J systematically converts third-party scientific discoveries into commercial blockbusters through its development and regulatory infrastructure. Genmab discovered the antibody; J&J built the clinical development program, secured the FDA approval, and deployed the global commercial organization to generate revenues that neither party could have reached independently. The $6.475 billion talc litigation settlement proposed in 2024 — if accepted by the required supermajority of claimants — would be the largest personal injury tort settlement in J&J's history. The Texas Two-Step bankruptcy strategy that J&J attempted twice and that two federal appellate courts rejected as bad-faith abuse ultimately gave way to a direct settlement approach.
Chairman and CEO
Leading J&J through its most significant transformation: the separation of the consumer health business (Kenvue) and refocusing on pharmaceuticals and medical devices. Managing the talc litigation resolution while investing heavily in the pharmaceutical pipeline.
Former Chairman and CEO
Oversaw J&J's growth from $67 billion to $94 billion in revenue, executed the $19.7 billion Synthes and $30 billion Actelion acquisitions, and navigated the opioid litigation crisis and COVID-19 vaccine development.
Former Chairman
Transformed J&J from a wound care company into a diversified healthcare conglomerate through decentralization and acquisition. Wrote the J&J Credo in 1943, which became the company's guiding philosophy and proved its value during the 1982 Tylenol crisis.
Former Chairman and CEO
Led J&J through the 1982 Tylenol poisoning crisis with a response that became the gold standard for corporate crisis management. His decision to recall 31 million bottles at $100 million cost, guided by the Credo, preserved J&J's reputation and Tylenol's market share.
Long-acting injectable antipsychotics — Invega Sustenna (once-monthly), Invega Trinza (once-quarterly), and Invega Hafyera (twice-yearly) — address the schizophrenia medication adherence problem with progressively longer dosing intervals that reduce treatment burden and discontinuation rates in a patient population with historically poor oral medication compliance. Surprisingly, the Stelara Biosimilar Cliff is J&J's most acute near-term financial challenge. In MedTech, Varipulse PFA adoption in atrial fibrillation ablation, Impella penetration in cardiogenic shock and high-risk PCI, and Shockwave Medical's intravascular lithotripsy expansion in severe coronary and peripheral calcification disease all represent high-clinical-need categories with large addressable markets where J&J enters with credibly differentiated technology. Yet the bear case centers on the Stelara transition execution risk, talc settlement completion uncertainty, and China MedTech structural headwinds. Lister's central argument was both simple and revolutionary: the infection and death that killed a substantial percentage of surgical patients in the 1870s was not caused by miasma or bad air or constitutional weakness, as most American surgeons believed, but by microscopic organisms — bacteria — that contaminated wounds during and after surgery, and that could be eliminated through systematic application of carbolic acid and other antiseptic agents.
Ralph Larsen served as Johnson & Johnson's chairman and CEO from 1989 to 2002, a period in which annual revenue grew from roughly $10 billion to about $36 billion. He expanded J&J heavily in medical devices and diagnostics, including the 1998 acquisition of DePuy. Larsen handed leadership to William Weldon in 2002.
William Weldon led Johnson & Johnson as CEO from 2002 to 2012 and oversaw the 2006 acquisition of Pfizer's consumer-health unit for about $16.6 billion, which brought in brands such as Listerine. His final years were marked by a wave of manufacturing quality problems and product recalls beginning in 2009. Weldon retired in 2012 and was succeeded by Alex Gorsky.
Alex Gorsky led Johnson & Johnson as CEO from 2012 to 2022, a period in which annual revenue rose past $90 billion. He drove large acquisitions, including the roughly $30 billion Actelion deal in 2017, and set in motion the strategic review that led to the Kenvue consumer-health separation. Gorsky stepped down as CEO in 2022.
Joaquin Duato became Johnson & Johnson's CEO in January 2022 after more than three decades at the company. He completed the Kenvue consumer-health separation in 2023 and pursued cardiovascular M&A, including the $13.1 billion Shockwave Medical acquisition in 2024. Duato has concentrated J&J on its Innovative Medicine and MedTech segments while managing the Stelara biosimilar transition.